Silvano Paternoster Ph.D.’s Post

🧫 A recent study from Misha Teale introduces a novel process intensification strategy for expanding human induced pluripotent stem cells (hiPSCs), showing great promise for improving the manufacturing of hiPSC-based therapeutics. The one-step inoculation (OSI) approach, typically used in antibody and vaccine production, has been successfully applied to hiPSC expansion, leading to significantly improved cell attachment and faster production. This method could revolutionize the way we produce hiPSC-based therapies at a large scale. 🌱 👨🔬 Ready to explore how our microcarriers could shape the future of hiPSC-based cell therapies? Connect with us to dive deeper into these innovations in biotech.🌐 https://lnkd.in/eGvr4Mkx #StemCells #hiPSCs #CellTherapy #Biotech #Innovation #Therapeutics #Research #RegenerativeMedicine #ProcessIntensification #Biomanufacturing #Microcarriers

📢Breakthrough Collaboration: Lonza and NeuroSense Therapeutics Revolutionize Neurodegeneration Research 🔬 NeuroSense Therapeutics Ltd has entered into a collaboration with Lonza AG to advance theranostics in neurodegeneration. 🧪 The collaboration will focus on identifying exosome-based biomarkers for early diagnosis and treatment. 💡 NeuroSense's lead candidate for ALS, Prime C, has shown promising results in Phase IIb studies. 🤝 The partnership will leverage Lonza's expertise in extracellular vesicles to develop methods for measuring biomarkers. 🧠 #BioprocessUpdates #LonzaAG #NeuroSenseTherapeutics #R&Dcollaboration #neurodegeneration #theranostics #exosome #biomarkers #earlydiagnosis #treatment #ALS #PrimeC #PhaseIIb #extracellularvesicles #measuringbiomarkers #researchanddevelopment ▷ Read the full article here: 📎 https://lnkd.in/dJxbcNcG

Engineering a novel platform for extracellular vesicles-mediated mRNA delivery: in their latest work, Antje Zickler, Samir EL Andaloussi at Karolinska Institutet and collaborators designed a bioengineering platform for efficient mRNA loading and functional delivery using extracellular vesicles. This system is established by expressing a highly specific RNA-binding domain fused to CD63 in EV-producing cells, which are engineered to stably express the target mRNA https://lnkd.in/ejEcP3AC Their findings provided strong evidence that extracellular vesicles are significantly more efficient at delivering nucleic acid therapeutics compared to lipid nanoparticles (LNPs). An article co-authored by Xiuming Liang, Dhanu Gupta, Doste Mamand, Mariacristina De Luca, PhD, Giulia Corso, Lorenzo Errichelli, Justin Hean, Titash Sen, PhD, Omnia ElSharkasy, Noriyasu Kamei, Zheyu Niu, Guannan Zhou, Houze Zhou, Samantha Roudi, Oscar Wiklander, André Görgens, Joel Nordin and Virginia Castilla Llorente #extracellularvesicles #exosomes #bioengineering #mRNA #drugdelivery #Vesiculab

𝐔𝐧𝐥𝐨𝐜𝐤 𝐍𝐞𝐱𝐭-𝐆𝐞𝐧 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬! Join us for an exclusive webinar on "Enhancing Next-Gen Antibody Therapies: Advanced Strategies for Fcγ Receptor Binding Assays" on 𝟐𝟑𝐫𝐝 𝐉𝐮𝐥𝐲, 𝐓𝐮𝐞𝐬𝐝𝐚𝐲 𝐚𝐭 𝟓 𝐏𝐌 𝐂𝐄𝐓.. Discover the cutting-edge techniques for Fcγ receptor binding studies, crucial for optimizing IgG1, IgG2, and IgG4 monoclonal antibodies. 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬: 1. Deep dive into IgG-Fcγ receptor interactions. 2. Best practices for assay design and development. 3. Real-time, label-free analysis using the Octet® BLI Platform. Don’t miss insights from Dr. Stuart Knowling, a leading biophysics expert! 👉 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐧𝐨𝐰: https://lnkd.in/gP8cE7hY #AntibodyResearch #FcγReceptors #DrugDevelopment #Biophysics #MonoclonalAntibodies #OctetBLI #Webinar #AssayDevelopment #PharmaScience #Biotech #ProteinAnalysis #Research #Immunotherapy #Biosimilars #Biopharma

FDA granted approval to Iovance Biotherapeutics, Inc.’ s lifileucel as the first one-time cell therapy for a solid tumor and the first tumor-infiltrating lymphocytes (TIL) therapy. Amtagvi, as lifileucel will be known commercially, was approved under the FDA's Accelerated Approval pathway, which allows the greenlighting of medicines for serious or life-threatening diseases based on surrogate endpoints that are reasonably likely to predict clinical benefit. Read: https://lnkd.in/efYg8kSp #sciencesdelavie #biotechnologie #biotechnology #innovation #innovations #recherche #sciences #medicaments #research #drugresearch #laboratories #labs #chemistry #chimie #biology #biologie #biopharma #rna #rnatherapeutics #arn #wewillwin

🚀 Exciting News from BioVivium Strategies! 🚀 We're thrilled to share a new breakthrough highlighted in our latest blog post: "Unlocking the Potential of ctDNA: Advancing Oncology Clinical Trials." Our Chief Scientific Officer led an innovative Design of Experiment (DOE), utilizing advanced flow cytometry techniques to enhance the viability and functionality of cryopreserved Peripheral Blood Mononuclear Cells (PBMCs). This DOE is pivotal for researchers and clinicians aiming to maximize the effectiveness of immunological assays and cellular therapies. 🔬 Why is this important? DOE methodologies are crucial for optimizing laboratory protocols and therapeutic applications. Our latest project exemplifies how strategic experiment design can lead to significant advancements in biotechnology and patient care. 🌟 What we offer: At BioVivium, we specialize in tailoring DOEs to meet the specific needs of our clients, ensuring precision, efficiency, and reproducibility. Our goal is to empower biotech companies to accelerate their R&D through scientifically sound strategies. Read more about how we're pushing the boundaries of biotech research and check out our services to see how we can support your projects: https://wix.to/piKsuY8 #Biotechnology #FlowCytometry #DOE #BioViviumStrategies #Innovation #ResearchAndDevelopment #newblogpost

🌍 Did you know that over 50 nanomedicines and nanotechnology-based medical products have already received regulatory approval worldwide? 👉🏽 A prime example is Onpattro®, a small interfering RNA-lipid nanoparticle for hereditary transthyretin amyloidosis. It constitutes the first-in-class RNA interference therapeutic, paving the way for many novel nanotechnology-based gene-silencing therapeutics. 👉🏽 An estimated 500 nanoparticle-based products are currently in clinical trials, highlighting that the interest and pursuit of successful nanoparticle technologies continues. At DIVERSA we made this pursuit our commitment and through our R&D platform we continuously thrive on innovation to improve the performance of our lipid nanosystems to efficiently deliver mRNA and other biomolecules, with the aim of advancing innovations to the clinic in the form of nanomedicines. 🚀 Our technology delivers mRNA in vitro and in vivo with a high potency and extends to a wide range of indications. Discover more about our lipid nanoparticles on our web 👇🏼 https://lnkd.in/gXdaHC3H #drugdelivery #nanoparticle #nanomedicie #nanotechnology

What challenges does the extracellular vesicle (EV) industry face, and how can they be addressed? The EV industry grapples with issues of standardization and scalability. Implementing universally accepted isolation and characterization protocols, alongside automated production processes, can enhance reproducibility and efficiency. For example, utilizing microfluidic technology for EV isolation can provide consistent and scalable results. Read more here: https://lnkd.in/e_m25nbS Arcellx Harvard Bioscience RoosterBio Inc. Exosome Diagnostics Flagship Pioneering MediBeacon Inc. Revolution Medicines Vesiculab #ExtracellularVesicles #EVs #Standardization #Scalability #Biotechnology #Therapeutics #ClinicalTranslation #ResearchInnovation #CellBiology #Biomanufacturing #STEM #lifescience #immunology #industry

𝐔𝐧𝐥𝐨𝐜𝐤 𝐍𝐞𝐱𝐭-𝐆𝐞𝐧 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬! Join us for an exclusive webinar on "Enhancing Next-Gen Antibody Therapies: Advanced Strategies for Fcγ Receptor Binding Assays" on  𝟐𝟑𝐫𝐝 𝐉𝐮𝐥𝐲, 𝐓𝐮𝐞𝐬𝐝𝐚𝐲 𝐚𝐭 𝟓 𝐏𝐌 𝐂𝐄𝐓.. Discover the cutting-edge techniques for Fcγ receptor binding studies, crucial for optimizing IgG1, IgG2, and IgG4 monoclonal antibodies. 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬: 1. Deep dive into IgG-Fcγ receptor interactions. 2. Best practices for assay design and development. 3. Real-time, label-free analysis using the Octet® BLI Platform. Don’t miss insights from Dr. Stuart Knowling, a leading biophysics expert! 👉 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐧𝐨𝐰: https://lnkd.in/gP8cE7hY #AntibodyResearch #FcγReceptors #DrugDevelopment #Biophysics #MonoclonalAntibodies #OctetBLI #Webinar #AssayDevelopment #PharmaScience #Biotech #ProteinAnalysis #Research #Immunotherapy #Biosimilars #Biopharma

FDA granted approval to Iovance Biotherapeutics, Inc.’ s lifileucel as the first one-time cell therapy for a solid tumor and the first tumor-infiltrating lymphocytes (TIL) therapy. Amtagvi, as lifileucel will be known commercially, was approved under the FDA's Accelerated Approval pathway, which allows the greenlighting of medicines for serious or life-threatening diseases based on surrogate endpoints that are reasonably likely to predict clinical benefit. Read: https://lnkd.in/e_Y9SwR3 #sciencesdelavie #biotechnologie #biotechnology #innovation #innovations #recherche #sciences #medicaments #research #drugresearch #laboratories #labs #chemistry #chimie #biology #biologie #biopharma #rna #rnatherapeutics #arn #wewillwin